Drug Profile
Research programme: transforming growth factor beta-1 antagonists - GlaxoSmithKline
Alternative Names: SB 431542; SB 505124Latest Information Update: 24 Jan 2008
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Benzamides; Dioxoles; Small molecules
- Mechanism of Action Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Wounds